Purchase Order HHSN268201700330A

<p>The National Heart Lung and Blood Institute awarded a purchase order to Illumina, Inc. valued at $82,758.00 on September 25, 2013, with an ultimate completion date of August 15, 2014. No set-aside was used. Work is performed in Bethesda, Maryland. The order procures DNA and RNA sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core portfolio of biotechnology products serving federal research and diagnostic operations.</p>

The National Heart, Lung, and Blood Institute awarded a purchase order to Illumina, Inc. for $95,569.54 on December 19, 2017, with an ultimate completion date of June 4, 2018. The order is firm fixed price, with no set-aside used. Place of performance is North Bethesda, Maryland. The purchase order covers an Illumina service contract involving sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core product line for federal genomic research and diagnostic...

<p>The National Heart Lung and Blood Institute issued a $18,909 delivery order to Illumina, Inc. on November 14, 2014, with an ultimate completion date of August 31, 2015. Place of performance is Bethesda, MD. The order is firm fixed price with no set-aside applied. The source does not identify the parent vehicle name or vehicle type under which this delivery order was issued.</p>

<p>The National Heart Lung and Blood Institute issued a $21,903 delivery order to Illumina, Inc. on October 27, 2014, for genetic sequencing reagents and consumables. Place of performance is Bethesda, MD. The order has a firm fixed price and an ultimate completion date of August 31, 2015. No set-aside was used for this delivery order.</p>

<p>The National Heart Lung and Blood Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $26,942 on July 25, 2019, for ImmunoSEQ Assay sequencing kits and reagents. This was a Total Small Business set-aside acquisition with firm fixed-price pricing. Place of performance is Seattle, Washington. The order was issued under a Total Small Business solicitation posted July 18, 2019, and carries an ultimate completion date of August 24, 2019.</p>

The National Heart Lung and Blood Institute awarded a purchase order to Illumina, Inc. valued at $190,561.89 on June 5, 2018, with final completion on June 4, 2019. The order is firm fixed-price with no set-aside designation. Place of performance is Bethesda, Maryland. The purchase order covers Illumina service contract requirements, typical of the vendor's federal work providing genetic sequencing systems, reagents, and bioinformatics support to research institutions across civilian agencies.

The National Heart, Lung and Blood Institute awarded a purchase order to Illumina, Inc. for $367,460.10 on July 13, 2010, for the iSelect Infinium Custom FastTrack Service Project, with ultimate completion on July 14, 2011. Work is performed in Framingham, Massachusetts. The order is firm fixed price with no set-aside designation. Illumina manufactures DNA and RNA sequencing instruments, reagents, consumables, and bioinformatics software; this purchase order procures custom sequencing services...

<p>The National Heart Lung and Blood Institute issued a $38,844 delivery order to Illumina, Inc. on November 4, 2014, for genetic sequencing and genomic analysis equipment and materials, with an ultimate completion date of August 31, 2015.</p> <p>Place of performance is Bethesda, Maryland. The order is firm fixed price with no set-aside designation. The source does not identify the parent vehicle under which this delivery order was issued.</p>

<p>The National Heart Lung and Blood Institute issued a $12,181 delivery order to Illumina, Inc. on September 19, 2014, for firm fixed-price procurement of genetic sequencing equipment and reagents.</p> <p>Place of performance is Bethesda, MD. The order has an ultimate completion date of August 31, 2015. No set-aside was used.</p>

<p>The National Heart Lung and Blood Institute issued a $23,099 delivery order to Illumina, Inc. on November 18, 2014, for genetic sequencing equipment and related supplies, with performance at Bethesda, MD and completion by August 31, 2015.</p> <p>The order is firm fixed price with no set-aside designation.</p>